Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cell Transplant: A Pilot Study

NCT07509450 | Recruiting DMC

• 2 other identifiers: FMT Pilot StudyOZUHN-038
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single site pilot trial will evaluate the feasibility and safety of fecal microbiota transplantation (FMT) in patients with B-cell lymphoma who are undergoing CAR-T or in patients with moderate to high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing allogeneic stem cell transplantation.

Conditions

Lymphoma Receiving CAR-T Therapy

Outcome Measures

Primary Outcomes (2)

• To evaluate the feasibility of fecal microbiota transplantation (FMT) in patients undergoing CAR-T or allogeneic stem cell transplantation.

  We hypothesize that we will be able to successfully recruit at least 50% of approached patients, retain at least 80% of patients on the study, and successfully administer at least one FMT series to 80% of retained patients.

  2.5 years

• To evaluate the safety of fecal microbiota transplantation (FMT) in patients undergoing CAR-T or allogeneic stem cell transplantation.

  We hypothesize that FMT will be safe in this population. Each cohort will be considered separately in considering the differing risks of CAR-T and alloSCT. We hypothesize that in each cohort there will be no greater than 10% incidence (N\< 1 of 10 participants in each cohort), of serious adverse events, or Grade \>3 adverse events of special interest (sepsis and/or bacteremia, ICU admission, bowel perforation, or death) within 48 hours of administration of FMT, which are judged to be possibly, probably or definitely related to FMT.

  2.5 years

Study Arms (2)

CAR-T cell transplant

EXPERIMENTAL

Patients will receive Fecal microbiota transplantation and CAR-T cell infusion

Biological: Fecal Microbial Transplant Enema

Allogenic stem cell transplant

EXPERIMENTAL

Patients will receive Fecal microbiota transplantation and allogenic cell trnsplant

Biological: Fecal Microbial Transplant Enema

Interventions

Fecal Microbial Transplant Enema BIOLOGICAL

Rectal infusion of FMT will be administered every 48 hours for 2 doses, on 2 separate occasions, detailed in the study calendar. For each series of FMT administrations, the first dose will be 100g and the second will be 50g. Each FMT will be delivered using a single dose (300 ml of prepared fecal filtrate containing 100g or 50g of stool from a donor) delivered using an enema bag and rectal catheter. The procedure, including preparation steps, will take less than 20 - 30 minutes. The second FMT administration will occur in either the inpatient or outpatient setting depending on whether the patient has been discharged from hospital by the time their second FMT series is due at Day +30. The second FMT series will only occur if patients have a neutrophil count of ANC\>1.0 x 109/L without growth factor support for the last 7 days, documented within 7 days prior to the FMT administration.

Allogenic stem cell transplant

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Men and women ≥ 18 years of age
• Diagnosis of the following:
• Indolent or aggressive B-cell lymphoma eligible for standard or care CAR-T therapy (Cohort A), or
• Patients with AML or high risk MDS with indication to undergo reduced-intensity conditioning alloSCT, with an available matched related, unrelated, or haploidentical donor (Cohort B)
• ECOG 0-1
• Adequate marrow function defined by:
• Hemoglobin \>80 g/L without transfusion dependence within the last 7 days
• Platelet count \>20 x 109/L without transfusion dependence within the last 7 days
• Neutrophil count \>1.0 x 109/L without growth factor support within the last 7 days
• Adequate liver function as indicated by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x the institutional upper limits of normal (ULNs) value; serum total bilirubin \< 1.5 x ULN (unless documented Gilbert's syndrome)
• Adequate renal function as defined as creatinine clearance ≥ 30 mL/min directly measured with a 24-hour urine collection or calculated according to the modified formula of Cockcroft-Gault equation or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) calculation
• Life expectancy \>6 months
• Women of childbearing potential (WOCBP) who are sexually active must use highly effective methods of contraception during treatment and up to 6 months after the last dose of protocol therapy. Men who are sexually active must use highly effective methods of contraception during treatment and up to 6 months after the last dose of protocol therapy. Men require an agreement to remain abstinent (ie, refrain from heterosexual intercourse) or use a condom, and an agreement to refrain from donating sperm. Periodic abstinence and withdrawal are not acceptable methods of contraception. Fertility preservation options should be discussed. Examples of highly effective contraceptive methods include an agreement to remain abstinent (ie, refrain from heterosexual intercourse), bilateral tubal ligation, male sterilization, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
• Willing and able to participate in all required evaluations and procedures in this study.
• Ability to understand and the willingness to sign a written informed consent.

You may not qualify if:

• For patients undergoing alloSCT (Cohort B): plan to undergo myeloablative conditioning
• Use of investigational agents within the last 4 weeks before enrollment.
• Active or uncontrolled infection
• Autoimmune disorder currently being treated with disease-modifying therapy or with \>10mg/day prednisone
• Inflammatory bowel disease
• History of intestinal perforation
• Gastrointestinal surgical procedure within the past 4 weeks before enrollment
• Pregnant or breast-feeding patients
• HIV infection with detectable viral load or CD4 count \<200
• Serologic status reflecting active hepatitis B or C infection as follows:
• Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with detectable hepatitis B virus (HBV) DNA. (Note, patients with undetectable HBV DNA are permitted to enroll if they are on Hepatitis B suppressive therapy)
• Patients with presence of hepatitis C virus (HCV) antibody and HCV RNA detectable
• History of infection or known colonization with antibiotic resistant organism in the last two years before enrollment (including ESBL, MRSA, VISA, VRSA, VRE, CPE)
• Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in the study

Sponsors & Collaborators

• University Health Network, Toronto: lead

Study Sites (1)

University Health Network

Toronto, Ontario, M5G 2M9, Canada

RECRUITING

Central Study Contacts

Abi Vijenthira, MD

CONTACT

416-946-4501; Abi.Vijenthira@uhn.ca

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: There will be 2 cohorts run parallely. Both cohorts patients will receive fecal microbiota transplantation (FMT). One cohort will receive stem cell transplant and the other one will receive CAR-T infusion.

Study Record Dates

• First Submitted: March 10, 2026
• First Posted: April 3, 2026
• Study Start: June 2, 2026
• Primary Completion (Estimated): June 2, 2029
• Study Completion (Estimated): June 2, 2029
• Last Updated: June 11, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)